Boston Scientific Corporation $BSX Stock Sold by ProShare Advisors LLC

ProShare Advisors LLC lessened its holdings in Boston Scientific Corporation (NYSE:BSX) by 5.8% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 246,502 shares of the medical equipment provider’s stock after selling 15,052 shares during the period. ProShare Advisors LLC’s holdings in Boston Scientific were worth $10,760,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in Boston Scientific in the 2nd quarter worth about $5,534,781,000. Primecap Management Co. CA bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $2,156,233,000. Jupiter Topco LLC bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $803,357,000. Janus Henderson Group PLC grew its holdings in shares of Boston Scientific by 31.0% during the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Finally, Amundi increased its position in shares of Boston Scientific by 1.2% in the second quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock worth $610,158,000 after purchasing an additional 173,208 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

BSX has been the topic of a number of recent analyst reports. TD Cowen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating and lowered their target price for the company from $56.00 to $46.00 in a research note on Friday, October 30th. Piper Sandler decreased their price target on shares of Boston Scientific from $65.00 to $60.00 and set an “overweight” rating on the stock in a report on Wednesday, July 29th. Raymond James Financial restated an “outperform” rating and set a $57.00 price objective (down from $78.00) on shares of Boston Scientific in a research report on Thursday, July 30th. Citigroup dropped their price objective on shares of Boston Scientific from $48.00 to $44.00 and set a “neutral” rating for the company in a report on Thursday, October 29th. Finally, Rothschild & Co Redburn cut their target price on shares of Boston Scientific from $106.00 to $78.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $61.43.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported that the SIMPLAAFY trial of its WATCHMAN FLX Pro heart device met its six-month primary endpoints. The results found two post-implant drug regimens non-inferior to dual-antiplatelet therapy, potentially supporting simpler treatment after the procedure. Article: SIMPLAAFY study results
• Neutral Sentiment: Boston Scientific and Blackstone Life Sciences announced a $455 million collaboration to co-develop the VITALYST heart-pump technology. The arrangement may ease near-term development costs, but an analyst noted it could defer growth and leave longer-term uncertainty. Article: VITALYST collaboration Article: Analyst assessment of VITALYST deal
• Negative Sentiment: A Zacks analysis flagged weakening earnings estimates, softer momentum in core businesses and major growth catalysts that may not arrive until 2028. Those concerns could overshadow the company’s valuation discount. Article: Valuation and earnings-growth analysis
• Negative Sentiment: J.P. Morgan maintained a Hold rating, while TD Cowen also cut its rating to Hold; Barclays lowered its price target. The cautious analyst stance adds to concerns about near-term growth. Article: J.P. Morgan rating Article: TD Cowen rating Article: Barclays price-target change

Boston Scientific Stock Down 1.7%

Shares of BSX opened at $43.58 on Wednesday. The firm has a market cap of $63.15 billion, a P/E ratio of 18.47, a P/E/G ratio of 1.29 and a beta of 0.60. The stock has a 50 day simple moving average of $44.55 and a two-hundred day simple moving average of $56.38. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1 year low of $39.57 and a 1 year high of $105.65.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, meeting analysts’ consensus estimates of $0.73. The business had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.73%. The business’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period last year, the business earned $0.75 earnings per share. On average, analysts forecast that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.